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respectively. In younger patients, median background and 
procedural COMFORT-B scores were 13.8 (range 10–23) 
and 14.8 (range 13–23, p = 0.03), respectively. Patient and 
Observer Scar Assessment Scale (POSAS) scores were 
favorable after 3 and 6 months post burn.
Conclusions Suprathel® provides potential advantages 
regarding pain and scar formation, but extensive wound 
debridement is needed to achieve adequate adherence.
Keywords Suprathel® · Partial thickness burns · Children · 
Usability · Effectiveness
Introduction
Although partial thickness burns are the most common 
burn injuries among children, there is no ‘gold standard’ for 
the optimal treatment of this type of burn injury [1, 2]. The 
treatment of partial thickness burns focuses on undisturbed 
wound healing by providing a moist wound environment, 
removal of exudate, prevention of infection, and minimiza-
tion of pain, scar formation and functional impairment [1, 
3, 4].
In the last few decades, significant progress has been 
made in the field of (semi)synthetic wound dressings to 
meet the above requirements. One of the latest innovations 
in this field is the development of Suprathel®. Suprathel® 
(PolyMedics Innovations GmbH, Filderstadt, Germany) 
is a biosynthetic, non-animal derived wound dressing that 
imitates the protective properties of the human epithelium 
by adhering to the wound bed at body temperature [5, 6]. 
The microporous membrane of Suprathel®, which has an 
elongation capacity of up to 250 %, is water-soluble and 
composed of a co-polymer (terpolymer) of poly-dl-lac-
tide, trimethylene carbonate and ε-caprolactone [5, 7]. The 
Abstract 
Purpose Evaluation of usability and effectiveness of 
Suprathel® in the treatment of partial thickness burns in 
children.
Methods A prospective, observational study to evaluate 
adherence of Suprathel® to the wound bed, reepithelializa-
tion time, grafting, wound colonization and infection, pain, 
dressing changes, length of hospital stay (LOS) and scar 
formation.
Results Twenty-one children (median age 2.4 years, range 
5 months–14 years) with a median total body surface area 
(TBSA) of 4 % (range 1–18) were included. Median LOS 
was 10 days (range 3–20). Median outer layer dressing 
changes was 3 (range 1–14). Suprathel® was only adher-
ent in wounds debrided with Versajet®. Median reepithe-
lialization time was 13 days (range 7–29). Three patients 
needed a split skin graft. There were 7 (33 %) patients 
with wound colonization before application of Suprathel®. 
This increased to 12 (57 %) patients during treatment. One 
patient developed a wound infection. Median visual analog 
scale (VAS) scores for background and procedural pain in 
patients >7 years were 3.2 (range 2–5) and 3.5 (range 2–5), 
 * Z. M. Rashaan 
 zrashaan@rkz.nl
1 Department of Surgery, Leiden University Medical Center, 
PO Box 9600, 2333 ZA Leiden, The Netherlands
2 Burn Centre, Red Cross Hospital Beverwijk, Vondellaan 3, 
PO Box 1074, 1942 LE Beverwijk, The Netherlands
3 Department of Surgery, Haga Teaching Hospital-Juliana 
Children’s Hospital, PO Box 60605, 2506 LP The Hague, 
The Netherlands
4 Associations of Dutch Burn Centers, PO Box 9100, 3079 
DZ Beverwijk, The Netherlands
Z. M. Rashaan et al.
1 3
porous property of Suprathel® is intended to prevent accu-
mulation of wound exudate and thereby preventing also 
wound infection. Also, a moist wound environment is sup-
posed to be established, which may contribute to an opti-
mal wound healing. Suprathel® is transparent after appli-
cation to the wound bed which enables inspection of the 
wound without removing the dressing [8].
Literature on effectiveness of Suprathel® in pediatric 
burn patients is scarce. Only two recent non-comparative 
studies reported good results in terms of wound healing in 
children with partial thickness burns [6, 9]. However, no 
studies reported validated data on the wound colonization, 
scar formation and pain after application of Suprathel® on 
the wound and before and after each outer layer dressing 
changes.
This study evaluates the usability and effectiveness of 
Suprathel® in the treatment of partial thickness burns in 
children.
Patients and methods
This observational, prospective study was conducted in the 
Juliana Children’s Hospital, The Hague and in the Bever-
wijk Burn Centre of the Red Cross Hospital, Beverwijk, 
The Netherlands.
Patients
Between November 2011 and January 2013, all consecutive 
patients younger than 18 years with partial thickness burns 
who were seen in these hospitals within 48 h after injury, 
were eligible for this study. Patients were excluded if they 
had only facial burns, if they previously had been treated 
elsewhere for their burn wounds or if they were expected to 
be non-compliant with their treatment, for example because 
of a profound language barrier.
Treatment protocol
All included patients underwent the same treatment protocol. 
Suprathel® was applied to the wound after administrating oral 
analgesics in the outpatient department or under general anes-
thesia (propofol, fentanyl) in the operating theatre within 48 h 
after injury. The burn wounds were cleaned by rinsing and 
superficial debridement of loose skin remnants and blisters or 
by using a Versajet® hydrosurgery system for surgical wound 
debridement [10]. Thereafter, a Suprathel® film was cut to 
adequate dimensions to cover the complete burned area, 
whereupon a multilayer Vaseline gauze dressing was applied 
to keep the Suprathel® separated from the outer absorbing 
dressings. Depending on the extension of the burns, patients 
were then either admitted to the ward or discharged and 
regularly seen in the outpatient clinic until complete wound 
healing. Thereafter, patients were seen at 3 and 6 months 
after injury. Suprathel® was left in situ until 95 % reepithe-
lialization had been achieved, while the outer dressings were 
changed routinely every 3–5 days. During these dressing 
changes, only outer layer dressings were removed, adherent 
Suprathel® was left untouched, and loose Suprathel® over the 
healed area was trimmed. If the Suprathel® was completely 
detached from the unhealed wound bed, it was removed after 
which the exposed wound was treated with a topical agent. 
At the 10th–14th day post burn, it was decided whether a 
skin graft was needed. Reasons for grafting were expected 
absence of progressive wound healing in the next 7–11 days 
and full thickness burns.
Swabs for semi-quantitative analysis of wound micro-
bial flora were taken on admission, before the applica-
tion of Suprathel® and during each outer layer dressing 
change. Wound colonization was defined as at least one 
positive bacterial culture from the wound [11]. Infection 
was defined as a combination of skin redness, pain, swell-
ing, tenderness, warmth, fever or pus draining from the 
skin with a positive wound colonization [12]. If infection 
occurred, Suprathel® was removed from the wound. Based 
on the outcome of the swabs, infected wounds were treated 
with an appropriate local antiseptic.
Data
Baseline characteristics were recorded including gender, age, 
cause and location of the burn, depth of the burns (superficial 
or deep partial thickness), time from burn to start of treat-
ment in days, and percentage of affected total body surface 
area (TBSA). Superficial partial thickness burns (SPTB) 
were clinically defined at the acute stage as painful burn 
wounds that had a moist pink colored appearance, with 
intact or disrupted blisters and with a capillary refill within 
less than seconds. Deep partial thickness burns (DPTB) were 
defined as painful wounds with a dry and red-to-pale appear-
ance with pale blotchy patches, with intact or disrupted blis-
ters and a capillary refill after more than 3 s [13].
Usability of Suprathel® was evaluated by its adherence 
to the wound bed and the number of (outer layer) dress-
ing changes. Effectiveness of Suprathel® was evaluated in 
terms of reepithelialization time, need for skin grafting, 
wound colonization and infection, pain, length of hospital 
stay (LOS) and scar formation.
Reepithelialization time was defined as the number of 
days until at least 95 % reepithelialization of the wound, 
judged by an experienced burn surgeon. The number of 
burn wounds that were treated with Suprathel® and required 
secondary (surgical) intervention were also determined. 
Pain was measured before each outer layer dressing change 
to measure background pain and after each outer layer 
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dressing change to evaluate procedural pain. Patients older 
than 7 years scored pain on a visual analog scale (VAS), a 
continuous horizontal 10-cm line ranging from 0 (no pain) 
to 10 (worst possible pain). The COMFORT-Behavior scale 
was scored by trained pediatric nurses to measure pain in 
younger patients. This COMFORT-B scale contains six 
behavioral items including alertness, calmness, respiratory 
response or crying, muscle tone, physical movement, and 
facial tension. For each item, the response categories range 
from 1 (‘no distress’) to 5 (severe distress) leading to an 
overall score ranging from of 6 to 30 [14].
Scar formation was assessed at 3 and 6 months post 
burn, using the Patient and Observer Scar Assessment 
Score (POSAS [15, 16]). The POSAS consists of an 
observer scale, which is scored by an experienced burn spe-
cialist, and a patient scale, which is scored by the patient. 
The observer scale includes items on vascularization, pig-
mentation, thickness, relief and pliability, while the patient 
scale measures pain, itching, color, stiffness, thickness and 
irregularity of the scar. The items on both scales are scored 
on a 10-point scale, ranging from 1 (‘normal skin’) to 10 
(‘worst imaginable scar’). Patients above 13 years of age 
score the patient scale themselves, whereas parents or car-
egivers fulfill this task for younger patients.
Statistical analysis
For this observational study, no formal sample size calcula-
tion was performed. A sample size of about twenty patients 
was considered sufficient to obtain insight into the usability 
and effectiveness of Suprathel® during the inclusion period. 
Data were stored in an SPSS database version 17 (SPSS 
Inc., Chicago IL) and described using summary statistics 
(median/range or number). Categorical data were compared 
between the groups using Fisher’s exact test. Comparison 
of the time to reepithelialization between SPTB and DPTB 
or wounds with/without bacterial colonization was per-
formed using the log-rank test. Pain scores before and dur-
ing application of Suprathel® on the wound bed were com-
pared within patients using the Wilcoxon signed-rank test 




Twenty-one patients (10 male, 11 female) with a median 
age of 2.4 years (range 5 months–14 years) were treated 
with Suprathel® during the inclusion period (Table 1). All 
patients were in good general health without comorbidities. 
Most burns were caused by scalding (n = 19) and affected 
the anterior trunk (n = 10) or the extremities (n = 17). 
Eleven (52 %) patients were treated in an outpatient setting, 
and ten (48 %) patients were admitted to hospital. Median 
TBSA at admission was 4 % (range 1.0–18.0). Median 
TBSA of the patients that were treated in outpatient set-
tings was 2.5 % (range 1.0–5.0), while median TBSA of 
admitted patients was 6.0 % (range 3.5–18.0). At the ini-
tial assessment, the burns of twelve (57 %) patients were 
classified as SPTB and as DPTB in nine (43 %) patients. 
Median LOS of the admitted patients was 10 days (range 
3–20).
Usability of Suprathel®
Adherence to wound bed
In most patients with SPTB (11/12, 92 %), a superficial 
wound debridement was performed, while the wounds of 
patients with DPTB were mostly debrided by Versajet® 
hydrosurgery (7/9, 78 %) (Table 2). The median time to 
application of Suprathel® on the wound was 1 day (range 
Table 1  Patient characteristics of 21 children with partial thickness 
burns
TBSA total body surface area, SPTB superficial partial thickness 
burns, DPTB deep partial thickness burns
Age, median (range) 2.4 years (5 months–14 years)
Gender, n (%)
 Male 10 (48)
 Female 11 (52)
Burn cause, n (%)
 Scald 19 (90)
 Flash 1 (5)
 Flame 1 (5)
Location of burn, n (%)
 Head and neck 2 (7)
 Trunk (anterior) 10 (33)
 Trunk (posterior) 1 (3)
 Upper extremities 9 (30)
 Lower extremities 8 (27)
Treatment, n (%)
 In outpatient clinic 11/21 (52)
 Admitted 10/21 (48)
% TBSA, median (range)
 In patients treated in outpatient 
clinic
2.5 (1.0–5.0)
 In admitted patients 6.0 (3.5–18.0)
 Total 4.0 (1.0–18.0)
Depth of burn, n (%)
 SPTB 12 (57)
 DPTB 9 (43)
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0–2) post burn. In nine (43 %) patients, Suprathel® was 
completely detached from the wound surface at the first 
outer layer dressing change (Table 2). All cases of complete 
detachment occurred in the group in which only superfi-
cial wound debridement had been performed (9/13, 69 %). 
In contrast, no detachment of Suprathel® from the wound 
was seen in the group in which debridement had been per-
formed by Versajet® hydrosurgery (0/8, p = 0.005).
Dressing changes
The median number of outer layer dressing changes 
was three (range 1–14) in patients in whom Suprathel® 
was adherent. However, in nine (43 %) patients in whom 
Suprathel® did not adhere to the wound bed, another dress-
ing was applied. The median number of these dressing 
changes was two (range 0–7) (Table 2).
Effectiveness of Suprathel®
Reepithelialization time and need for skin grafting
The median reepithelialization time was 13 days (range 
7–29). No significant difference in time to reepithelialization 
was found between SPTB and DPTB, 11 days (range 7–29) 
and 15 days (12–19; p = 0.26), respectively. The median 
time to reepithelialization was 15 days (range 9–29) for 
wounds with bacterial colonization, and 13 days (range 
7–18) for non-colonized wounds (p = 0.45). One patient, 
who suffered a wound infection, healed in 29 days. All 
SPTB healed without surgical intervention, whereas three of 
the patients with DPTB needed a split skin graft.
Colonization and infection
Seven (33 %) patients showed wound colonization before 
application of Suprathel® to the wound. During treat-
ment with Suprathel®, the number of patients with wound 
colonization increased to 12 (57 %). Various microorgan-
isms were found in the colonized wounds: Staphylococ-
cus aureus, Pseudomonas and group B streptococcus, and 
Acinetobacter baumannii. One patient in the DPTB group 
showed signs of infection with S. aureus.
Pain
Patients younger than 7 years had a median background 
COMFORT-B score of 13.8 (range 10–23), while their 
median procedural score was 14.8 (range 13–23, p = 0.03). 
There was no difference between pain scores given by the 
older patients before (median 3.5, range 2–5) and dur-
ing (median 3.2, range 2–5) outer layer dressing changes 
(p = 1).
Scar formation
Table 3 presents the median POSAS scores at 3 and 
6 months post burn. Most of the POSAS scores by observ-
ers and patients/parents were mainly in the lower third of 
the range, reflecting a good scar quality after 6 months post 
burn.
Discussion
Suprathel® is a potentially good alternative for biological 
wound dressing, because it is not derived from animals and, 
therefore, acceptable for all patient groups. To the best of 
our knowledge, this study is the only detailed prospective 
study including long-term results on the usability and effec-
tiveness of Suprathel® in the treatment of partial thickness 
burns in children. The data resulting from this study, which 
were obtained by validated measurement tools when pos-
sible, provide more insight into the usability and effective-
ness of this treatment in daily practice and can be used to 
design future comparative studies with other types of dress-
ings in the treatment of partial thickness burns in children.
Table 2  Measures of usability and effectiveness of Suprathel® in 21 
children with partial thickness burns
SPTB superficial partial thickness burns, DPTB deep partial thickness 
burns, PBD post burn day, TBSA total body surface area
Debridement, n (%)
 SPTB
  Superficial debridement 11/12 (92)
  Versajet® hydrosurgery 1/12 (8)
 DPTB
  Superficial debridement 2/9 (22)
  Versajet® hydrosurgery 7/9 (78)
Time until application of Suprathel® in PBD,  
median (range)
1 (0–2)
TBSA of wound area treated with Suprathel®,  
median (range)
4 (1–18)
Adherence till wound healing, n (%)
 Yes 12 (57)
 No 9 (43)
Number of dressing changes, median (range)
 During Suprathel® adherence 3 (1–14)
 After detachment of Suprathel® 2 (0–7)
Time to reepithelialization in days, median (range)
 Total 13 (7–29)
 Wound without bacterial colonization 13 (7–18)
 Wound with bacterial colonization 15 (9–29)
Split skin graft, n (%) 3 (14)
Length of hospital stay, median (range) 10 (3–20)
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The lack of adherence of Suprathel® to the wound 
bed seems to be attributable to the extent of debridement 
technique. Adherence of Suprathel® was achieved when 
the Versajet® system had been used, while no adherence 
was seen in most cases when superficial debridement had 
been performed. Three studies reported on the adherence 
of Suprathel® to the wound bed in the treatment of par-
tial thickness wounds and found excellent material adher-
ence [6, 7, 9]. However, the effect of the extent of wound 
debridement on the adherence is not clear in these stud-
ies, because either different debridement techniques were 
used or no information was reported on the debridement 
technique. Our study suggests that extensive wound bed 
debridement might be a requirement for adequate adher-
ence of Suprathel® to the wound.
The results regarding time to reepithelialization in our 
study were comparable to those of a previous non-com-
parative study on the treatment of partial thickness burns 
in children with Suprathel® [6, 9]. In two recent system-
atic reviews on the treatment of partial thickness burns 
in children, the mean time to reepithelialization in rand-
omized controlled trials (RCT) that used other (semi)syn-
thetic dressings varied between 7.5 and 23.6 days [1, 17]. 
In adults, no difference in reepithelialization was found 
when Suprathel® was compared to other (semi)synthetic 
dressings (Biobrane® [18] and Omiderm®) [19] or split-
thickness skin graft (STSG) [8] in the treatment of partial 
thickness burns. In pediatric patients, a short reepitheliali-
zation time is important as other studies have shown a low 
risk of developing hypertrophic scars and contractures in 
burn wounds that healed within 21 days [20, 21]. Our study 
seems to confirm this finding as healing of the burn wound 
in one patient took more than 21 days, due to wound infec-
tion, after which this patient developed a hypertrophic scar 
and had the worst POSAS score in our study.
Three children (14 %) in our study received a skin graft, 
because no spontaneous wound healing was expected 
within 21 days after the burn injury. In other studies, the 
need for skin grafting varied between 0 and 17 % in chil-
dren with partial thickness burns that were treated with 
other (semi)synthetic dressings than Suprathel® [22–25]. 
However, comparing these results with the current study 
should be done with caution, because in these studies, no 
indication for and timing of skin grafting were reported. 
In our hospital, the standard care for the partial thickness 
burns is aimed to achieve reepithelialization, with or with-
out skin grafting, within 21 days. The aims of relatively 
early skin grafting are to allow the superficial area to heal, 
to reduce the risk of infection and inflammatory syndrome 
and to improve the functional result by minimizing the risk 
of scar formation [26]. This approach may have led to a rel-
atively high number of skin grafts in our study.
Scar formation is one of the most important outcomes 
that is evaluated rarely in children with partial thickness 
burns [1]. Adequate follow-up and evaluation of the scars 
with validated measurement tools are vital to manage scar 
formation. Cubison et al. demonstrated that hypertrophic 
scars had developed four months post burn in children with 
a TBSA of more than 5 % [27]. Therefore, we evaluated 
our patients at 3 and 6 months post burn. To our knowl-
edge, no previous study evaluated the scar formation with 
a validated method in pediatric patients with partial thick-
ness burns that were treated with Suprathel®. In adults, 
treatment with Suprathel® has shown a better scar quality 
compared to STSG in the treatment of partial thickness 
burns after 90 days post burn [8]. On the other hand, two 
other studies have shown no difference in hypertrophic scar 
formation when Suprathel® was compared to Omiderm® 
or Biobrane® in the treatment of partial thickness burns 
in adults [18, 19]. We found favorable scar quality in our 
study after 6 months post burn according to the POSAS 
scores.
Suprathel® forms a surrogate, natural barrier for micro-
organisms, that is intended to prevent accumulation of 
wound exudate and contains polylactic acid which reduces 
the local wound pH [28]. These properties may theoreti-
cally minimize the risk of wound colonization and wound 
infection and may, therefore, support optimal reepithe-
lialization. However, an in vitro study by Ryssel et al. 
showed insufficient evidence for an antiseptic effect of 
Table 3  Scores on the Patient and Observer Scar Assessment Score 
(POSAS) for evaluation of scar formation in 21 children with partial 
thickness burns treated with Suprathel®
3 months post burn 6 months post 
burn
Observer
Vascular, median (range) 3 (2–6) 2.5 (1–7)
Pigmentation, median 
(range)
3 (2–7) 2.5 (2–8)
Thickness, median (range) 3 (1–6) 2.5 (1–4)
Relief, median (range) 2 (1–6) 2.5 (1–4)
Pliability, median (range) 2 (1–8) 2 (1–5)
Surface, median (range) 2 (1–7) 2 (1–3)
Overall opinion, median 
(range)
3 (1–7) 2.5 (1–5)
Patient/parents
Pain, median (range) 1 (1–8) 1 (1–2)
Itching, median (range) 3 (1–8) 2.5 (1–5)
Color, median (range) 6 (3–8) 6 (2–9)
Pliability, median (range) 2 (1–6) 2.5 (1–8)
Thickness, median (range) 2 (1–8) 3 (1–8)
Irregularity, median (range) 2 (1–9) 3 (1–8)
Overall opinion, median 
(range)
4.5 (2–9) 3.5 (1–7)
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Suprathel® [28]. Our study seems to support these results 
since the number of patients with a colonized wound did 
not decrease after application of Suprathel®. Nevertheless, 
the current study found no apparent difference in reepi-
thelialization between wounds with and without bacterial 
colonization. The role of microorganisms in delayed wound 
healing is not clearly established [29]. Some studies found 
that the concentration of microorganisms is an important 
determinant for wound healing process [30–32], while 
other studies found the role of microorganisms less impor-
tant in delayed wound healing [33–35]. On the contrary, the 
only patient with wound infection in our study had delayed 
reepithelialization. In the literature, the association of burn 
wound infection and delayed reepithelialization is well 
established [36, 37].
This study found minimal changes between background 
pain and procedural pain. There was a statistically signifi-
cant increase in COMFORT-B scores in the youngest chil-
dren, but the difference in scores was minimal and may 
not be clinically relevant. Everett et al. also found minimal 
pain levels after application of Suprathel® on the wound 
in the treatment of partial thickness burns in children [9]. 
An explanation for these minimal changes between back-
ground pain and procedural pain might be that no manipu-
lation of the wound bed occurs when Suprathel® adheres 
to the wound bed. Manipulation of the wound bed is the 
main cause of the procedural pain which is the most intense 
pain in burn patients [38, 39]. Inadequate management of 
burn injury pain increases patients’ anxiety for the dress-
ing changes, reduces the effectiveness of analgesia and, in 
the long-term, changes pain perception and related behav-
iors [40–42]. Thus, novel burn treatments focus on reduc-
ing burn injury pain, for instance, by reducing the num-
ber of dressing changes. One study described analgesic 
response of the outer layer dressing changes as “very good” 
to “excellent” in children with partial thickness burns that 
were treated with Suprathel®. However, pain was not scored 
with a validated measurement tool in this study [6]. Studies 
in adult patients have shown lower pain scores for patients 
that were treated with Suprathel® compared to Omiderm® 
and Mepilex® in the treatment of partial thickness burns and 
donor sites of skin grafts, respectively [7, 43].
Since Suprathel® is porous and permeable to fluid, it 
requires an outer layer absorbing dressing to absorb the 
extensive amount of wound exudate. The number of outer 
layer dressing changes is not previously described in stud-
ies in patients with partial thickness burns that were treated 
with Suprathel®. The number of outer layer dressing 
changes in our study is comparable with the mean number 
of dressing changes between 1.5 and 7.5 in RCTs that used 
(semi)synthetics dressings in the treatment of partial thick-
ness burns in children [23, 24, 44, 45].
A limitation of this study is the small sample size so 
that the power of the study was too low to detect clini-
cally relevant differences between subgroups of patients. 
Another limitation of this study is that the burn depth was 
evaluated only by clinical assessment. It has been dem-
onstrated that the combination of the clinical assessment 
and laser Doppler imaging (LDI), that evaluates the dif-
ference in perfusion of the microvascular blood flow of 
the wound, is more accurate and reliable way to evaluate 
the burn depth than clinical evaluation only [46]. Finally, 
no comparison with other (semi) synthetic wound dress-
ing is performed due to the non-comparative nature of this 
study.
Conclusions
Our study on the usability and effectiveness of Suprathel® 
in the treatment of partial thickness burns in pediatric 
patients found potential advantages of Suprathel® treatment 
regarding pain and scar formation as compared to pub-
lished results on (semi)synthetic dressings in the literature. 
No clear advantages were found regarding reepithelializa-
tion, need for grafting, wound colonization and infection 
and dressing changes. Also, extensive wound debridement 
is needed to achieve adequate Suprathel® adherence. Rand-
omized controlled trials are needed to evaluate the efficacy 
of Suprathel® compared to other (semi)synthetic dress-
ings in the treatment of partial thickness burns in pediatric 
patients.
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